Cargando…
Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism
Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK). Case Report: A 34-ye...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Division of Ochsner Clinic Foundation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477128/ https://www.ncbi.nlm.nih.gov/pubmed/36189093 http://dx.doi.org/10.31486/toj.21.0107 |
_version_ | 1784790289157718016 |
---|---|
author | Long, Miranda Martin, Jane Biggio, Joseph |
author_facet | Long, Miranda Martin, Jane Biggio, Joseph |
author_sort | Long, Miranda |
collection | PubMed |
description | Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK). Case Report: A 34-year-old gravida 4, para 2012 underwent a repeat cesarean section at 39 weeks of gestation. After delivery of the placenta, hypoxia and hypotension developed, followed by cardiac arrest. Protocols for management of maternal cardiac arrest were followed. Echocardiogram demonstrated right ventricular dilation and hypokinesis. AOK was administrated during prolonged cardiac arrest, and spontaneous circulation returned. The patient was extubated on postoperative day 3 and discharged on postoperative day 10 without neurologic deficits. Conclusion: Management of AFE should include consideration of the addition of AOK to typical guidelines. |
format | Online Article Text |
id | pubmed-9477128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academic Division of Ochsner Clinic Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-94771282022-09-29 Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism Long, Miranda Martin, Jane Biggio, Joseph Ochsner J Case Reports and Clinical Observations Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK). Case Report: A 34-year-old gravida 4, para 2012 underwent a repeat cesarean section at 39 weeks of gestation. After delivery of the placenta, hypoxia and hypotension developed, followed by cardiac arrest. Protocols for management of maternal cardiac arrest were followed. Echocardiogram demonstrated right ventricular dilation and hypokinesis. AOK was administrated during prolonged cardiac arrest, and spontaneous circulation returned. The patient was extubated on postoperative day 3 and discharged on postoperative day 10 without neurologic deficits. Conclusion: Management of AFE should include consideration of the addition of AOK to typical guidelines. Academic Division of Ochsner Clinic Foundation 2022 2022 /pmc/articles/PMC9477128/ /pubmed/36189093 http://dx.doi.org/10.31486/toj.21.0107 Text en ©2022 by the author(s); Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/©2022 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Case Reports and Clinical Observations Long, Miranda Martin, Jane Biggio, Joseph Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism |
title | Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism |
title_full | Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism |
title_fullStr | Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism |
title_full_unstemmed | Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism |
title_short | Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism |
title_sort | atropine, ondansetron, and ketorolac: supplemental management of amniotic fluid embolism |
topic | Case Reports and Clinical Observations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477128/ https://www.ncbi.nlm.nih.gov/pubmed/36189093 http://dx.doi.org/10.31486/toj.21.0107 |
work_keys_str_mv | AT longmiranda atropineondansetronandketorolacsupplementalmanagementofamnioticfluidembolism AT martinjane atropineondansetronandketorolacsupplementalmanagementofamnioticfluidembolism AT biggiojoseph atropineondansetronandketorolacsupplementalmanagementofamnioticfluidembolism |